Prasurel

Prasugrel Hydrochloride ·Incepta Pharmaceuticals Ltd.·Tablet

0 views 0 reviews

Administration

Treatment should be initiated with a single 60 mg oral loading dose. Continue at 10 mg once daily with or without food. Consider 5 mg once daily for patients <60 kg. Patients should also take aspirin (75 mg to 325 mg) daily.

Effects

Bleeding
Thrombotic thrombocytopenic purpura
Other side effects (Headache, back pain, dyspnea, nausea, hypertension, bradycardia, rash etc)

In rats, lethality was observed after administration of 2000 mg/kg. Platelet transfusion may restore clotting ability. The prasugrel active metabolite is not likely to be removed by dialysis.

Indications

Prasugrel is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows:

Patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI).
Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI.

Pharmacology

Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of ADP receptors on platelets.

Precautions

CABG-related bleeding: Risk increases in patients receiving Prasugrel who undergo CABG.
Discontinuation of Prasugrel: Premature discontinuation increases risk of stent thrombosis, MI, and death